Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 1, 2009, Pages 63-80

  Shang, Elizabeth Y ^a   Gibbs, Megan A ^a,b   Landen, Jaren W ^a   Krams, Michael ^a,c   Russell, Tanya ^a   Denman, Nicholas G ^d   Mould, Diane R ^e  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b AMGEN INC   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Projections Research Inc   (United States)

Author keywords

Disease progression model; HAMD; Major depressive disorder; Model discrimination; NONMEM

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; PLACEBO;

ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALGORITHMS; COMPUTER SIMULATION; DEPRESSIVE DISORDER, MAJOR; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PLACEBO EFFECT; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61449255220     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9110-3     Document Type: Article

References (41)

1. A Khan K Schwartz 2005 Study designs and outcomes in antidepressant clinical trials Essent Psychopharmacol 6 221 226
2. RH Dworkin J Katz MJ Gitlin 2005 Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain Neurology 65 S7 S19 10.1212/01.wnl.0000177925.92714.a9
3. A Khan M Detke SR Khan C Mallinckrodt 2003 Placebo response and antidepressant clinical trial outcome J Nerv Ment Dis 191 211 218 10.1097/00005053-200304000-00001
4. DF Klein ME Thase J Endicott L Adler I Glick A Kalali S Leventer J Mattes P Ross A Bystritsky 2002 Improving clinical trials: American Society of Clinical Psychopharmacology recommendations Arch Gen Psychiatry 59 272 278 10.1001/archpsyc.59.3.272
5. GJ Emslie ND Ryan KD Wagner 2005 Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy J Clin Psychiatry 66 Suppl 7 14 20
6. JG Storosum AJ Elferink BJ van Zwieten W van den Brink J Huyser 2004 Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies Pharmacopsychiatry 37 32 36 10.1055/s-2004-815472
7. DF Klein 1999
8. JH Greist JC Mundt K Kobak 2002 Factors contributing to failed trials of new agents: can technology prevent some problems? J Clin Psychiatry 63 Suppl 2 8 13
9. MH Trivedi H Rush 1994 Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 11 33 43
10. FDA (1997) Guidance for industry: guideline for the clinical evaluation of antidepressant drugs. February 1997. U.S. Department of Health, Education, and Welfare, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). http://www.fda.gov/cder/guidance/old050fn.pdf. Accessed 15 Oct 2008
11. M Hamilton 1967 Development of a rating scale for primary depressive illness Br J Soc Clin Psychol 6 278 296
12. Holford N, Li J, Benincosa L, Birath M (2002) Population disease progress models for the time course of HAMD score in depressed patients receiving placebo in anti-depressant clinical trials. In: Abstracts of the XI annual meeting of the population approach group in Europe. Abstr. 311 www.page-meeting.org/?abstract=311. Accessed 15 Oct 2008
13. DR Mould 2007
14. Shang E, Gibbs MA, Landen J, Denman NG, Krams M, Russell T, Mould DR (2006) Model based analysis of placebo response in major depression. In: Abstract of the American College of Clinical Pharmacology annual meeting, Cambridge, MA
15. Cosson V, Gomeni R (2005) Modelling placebo response in depression using a mechanistic longitudinal model approach. In: Abstracts of the XIV annual meeting of the population approach group in Europe. Abstr. 818 www.page-meeting.org/?abstract=818. Accessed 15 Oct 2008
16. DE Mager E Wyska WJ Jusko 2003 Diversity of mechanism-based pharmacodynamic models Drug Metab Dispos 31 510 518 10.1124/dmd.31.5.510
17. NL Dayneka V Garg WJ Jusko 1993 Comparison of four basic models of indirect pharmacodynamic responses J Pharmacokinet Biopharm 21 457 478 10.1007/BF01061691
18. MO Karlsson V Molnar J Bergh A Freijs R Larsson 1998 A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression Clin Pharmacol Ther 63 11 25 10.1016/S0009-9236(98) 90117-5
19. SH Preskorn 1996 A dangerous idea J Pract Psychiatry Behav Health 2 231 234
20. Anonymous (1997) The appearance of knowledge. J Pract Psychiatry Behav Health 3:233-238
21. LB Sheiner B Rosenberg VV Marathe 1977 Estimation of population characteristics of pharmacokinetic parameters from routine clinical data J Pharmacokinet Biopharm 5 445 479 10.1007/BF01061728
22. LB Sheiner S Beal B Rosenberg VV Marathe 1979 Forecasting individual pharmacokinetics Clin Pharmacol Ther 26 294 305
23. SL Beal LB Sheiner 1980 The NONMEM system Am Stat 34 118 119 10.2307/2684123
24. Beal SL, Boeckman AJ, Sheiner LB (1998) NONMEM: user's guide part I-VIII. University of California at San Francisco, San Francisco
25. A Yafune M Ishiguro 1999 Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: a use of bootstrap standard error Stat Med 18 581 599 10.1002/(SICI)1097-0258(19990315)18:5<581: :AID-SIM47>3.0.CO;2-1
26. Karlsson MO (2005) Model-building diagnostics. In: DIA meeting, Philadelphia, PA
27. MO Karlsson RM Savic 2007 Diagnosing model diagnostics Clin Pharmacol Ther 82 17 20 10.1038/sj.clpt.6100241
28. F Mentre A Mallet D Baccar 1997 Optimal design in random-effects regression models Biometrika 84 429 442 10.1093/biomet/84.2.429
29. S Retout S Duffull F Mentre 2001 Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs Comput Methods Programs Biomed 65 141 151 10.1016/S0169-2607(00)00117-6
30. Hooker A, Dodds MG, Vicini P (2004) Evaluating the predictive power of the Fisher information matrix in population optimal experimental design. In: Abstracts of the XIII annual meeting of the population approach group in Europe. Abstr. 526 www.page-meeting.org/?abstract=526. Accessed 15 Oct 2008
31. S Retout F Mentre R Bruno 2002 Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics Stat Med 21 2623 2639 10.1002/sim.1041
32. Duffull S, Denman NG, Eccleston JA, Kimko H (2006) WinPOPT user guide. University of Otago, Dunedin, New Zealand
33. Y Yano SL Beal LB Sheiner 2001 Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J Pharmacokinet Pharmacodyn 28 171 192 10.1023/A:1011555016423
34. Holford N (2005) The visual predictive check-superiority to standard diagnostic (Rorschach) plots. In: Abstracts of the XIV annual meeting of the population approach group in Europe. Abstr. 738 www.page-meeting.org/?abstract= 738. Accessed 15 Oct 2008
35. Holford N (2005) The time course of placebo response in clinical trials-do antidepressants really take two weeks to work? In: AAPS annual meeting and exposition, Nashville, TN. http://www.aapspharmaceutica.com/inside/focus- groups/ModelSim/imagespdfs/Holford05.pdf. Accessed 15 Oct 2008
36. B Gruwez A Dauphin M Tod 2005 A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol J Pharmacokinet Pharmacodyn 32 663 683 10.1007/s10928-005-0006-6
37. Jacqmin P, Gieschke R, Jordan P, Steimer JL, Goggin T, Pillai G, Snoeck E, Girard P (2001) Modeling drug induced changes in biomarkers without using drug concentrations: introducing the K-PD model. In: Abstracts of the X annual meeting of the population approach group in Europe. Abstr. 232 www.page-meeting.org/?abstract=232. Accessed 15 Oct 2008
38. G Pillai R Gieschke T Goggin P Jacqmin RC Schimmer JL Steimer 2004 A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis Br J Clin Pharmacol 58 618 631 10.1111/j.1365-2125.2004.02224.x
39. EN Jonsson LB Sheiner 2002 More efficient clinical trials through use of scientific model-based statistical tests Clin Pharmacol Ther 72 603 614 10.1067/mcp.2002.129307
40. DR Mould NG Denman S Duffull 2007 Using disease progression models as a tool to detect drug effect Clin Pharmacol Ther 82 81 86 10.1038/sj.clpt.6100228
41. Denman NG, Mould DR, Duffull S (2006) Study designs to assess the placebo response (PBO-R) for Hamilton Depression (HAMD) Scores for depression. AAPS Journal 8 (S2) Abstr T3371